| breast cancer - HER2-positive | breast cancer - HR positive | breast cancer - triple negative | |||
| es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HR positive | la/mBC - HR positive - L2 - all population | mBC - Triple negative (TNBC) - 1st Line (L1) | es-BC - TNBC - NA - all population | |
| chemotherapy | |||||
| non platinum-based chemotherapy | |||||
| microtubul inhibitor | |||||
| eribulin | NCT03051659 | ||||
| taxanes | |||||
| paclitaxel | |||||
| nab-paclitaxel | TORCHLIGHT TORCHLIGHT | ||||
| paclitaxel followed by doxorubicin plus cyclophosphamide | IMpassion-050 IMpassion-050 IMpassion-050 | ALEXANDRA/IMpassion-030 | |||
| pegylated liposomal doxorubicin and cyclophosphamide | ICON | ||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
